Sara Silbert, MD, Gregory A. Yanik, MD, and Andrew G. Shuman, MD
“Living” drugs target specific B-cell malignancy tumor antigens, but cost hundreds of thousands of dollars. Value analysis can help determine whether to offer these customized drugs.
AMA J Ethics. 2019;21(10):E844-851. doi:
10.1001/amajethics.2019.844.
Martin Bricknell, PhD, David Whetham, PhD, Richard Sullivan, PhD, and Peter Mahoney, PhD
International humanitarian law obliges clinicians to coordinate with local civilian, military, and nongovernment organizations, and implementation isn't easy.
AMA J Ethics. 2022;24(6):E472-477. doi:
10.1001/amajethics.2022.472.
Jing Li, PhD, Robert Tyler Braun, PhD, Sophia Kakarala, and Holly G. Prigerson, PhD
For dying patients and their loved ones to make informed decisions, physicians must share adequate information about prognoses, prospective benefits and harms of specific interventions, and costs.
AMA J Ethics. 2022;24(11):E1040-1048. doi:
10.1001/amajethics.2022.1040.